GenesisCare - logo
Enquire now
Refer a patient

Your state: AU |

down arrow down arrow

Breast Cancer

Breast Cancer
2025-02-21T00:00:00.000+11:00
Ongoing

RAD202

RAD202
Breast

Phase 0/1 Study of the Safety and Tolerability of 177Lu-RAD202, a Lutetium-177 Radiolabeled Single Domain Antibody Against Human Epidermal Growth Factor Receptor 2 in Solid Tumors.

Phase 0/1 Study of the Safety and Tolerability of 177Lu-RAD202, a Lutetium-177 Radiolabeled Single Domain Antibody Against Human Epidermal Growth Factor Receptor 2 in Solid Tumors.

Trial overview

Clinical Area

Theranostics

Disease

Breast

Disease site

Breast

Study Phase

0

Trial Identifiers

Registration number: NCT06824155

https://clinicaltrials.gov/study/NCT06824155

GenesisCare Location(s)
Principal Investigator(s)
Nuclear Medicine Physician

Dr Aviral Singh

MD PGDipCard MSc FAfNM FRACP - Clinical Head of Theranostics and Nuclear Medicine

Dr Aviral Singh
Aviral
Singh
View Profile
Profile Image - Dr Aviral Singh

Clinical trials enquiries

Thank you for submitting.

We will be in touch within 24 hours

An unexpected error has occurred.

You will need to complete the form again, sorry for the inconvenience.

How can we help?

If you have a medical emergency please call 000. If you have an urgent request and would like to speak to our staff, please contact one of our centres directly.

* Indicates a required field.


 

Disclaimer:

This website is provided for information purposes only. Nothing on this website is intended to be used as medical advice, or to diagnose, treat, cure or prevent any disease. It should not be used as a substitute for your own health professional's advice. Any medical procedure or treatment carries risks. Before proceeding with treatment, you should discuss the risks and benefits of the treatment with an appropriately qualified health practitioner. Individual treatment outcomes and experiences will vary.

You are leaving our website

You are now leaving our website. GenesisCare do not control this content and therefore are not responsible for its accuracy or reliability.